A Combined Analysis of Serum Growth Differentiation Factor-15 and Cancer Antigen 15-3 Enhances the Diagnostic Efficiency in Breast Cancer.
CA15.3
breast cancer
diagnosis
growth differentiation Factor-15
Journal
EJIFCC
ISSN: 1650-3414
Titre abrégé: EJIFCC
Pays: Italy
ID NLM: 101092742
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
entrez:
25
11
2021
pubmed:
26
11
2021
medline:
26
11
2021
Statut:
epublish
Résumé
Existing diagnostic biomarkers of breast cancer (BC) are limited by poor sensitivity. In this study, we evaluated the role of serum GDF-15 in early BC diagnosis, independently and in combination with CA15-3, a known blood biomarker of BC. A total of 113 diagnosed, pre-therapy BC patients and 54 healthy controls were recruited. Clinical characteristics, TNM staging, and hormone receptor status of the patients were recorded. Serum GDF-15 and serum CA15-3 were measured by sandwich ELISA and chemiluminescence assay, respectively. The serum GDF-15 levels were significantly (p<0.001) elevated in BC patients compared to healthy controls and in patients with larger tumor size, advanced disease stage, and distant metastasis. ROC analysis revealed that at the cut-off of 525.77 pg/mL, GDF-15 had greater sensitivity than CA15-3. GDF-15 and CA15-3 performed better in combination than individually, with the combined test having an AUC of 0.85 and sensitivity and specificity of 0.63 and 0.98, respectively.Further, serum GDF-15 had a better predictive ability for early-stage BC compared to CA15-3. GDF-15 could independently diagnose BC patients after adjusting for age. We conclude that serum GDF-15 is a promising, robust marker for detecting early-stage BC. However, larger prospective studies are necessary to validate this claim.
Types de publication
Journal Article
Langues
eng
Pagination
363-376Informations de copyright
Copyright © 2021 International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). All rights reserved.
Déclaration de conflit d'intérêts
We acknowledge the support of all the technical staff at IPD Biochemistry Laboratory, AIIMS Jodhpur.
Références
BMC Vet Res. 2012 Jun 22;8:86
pubmed: 22726603
Oncotarget. 2017 Apr 11;8(15):24869-24881
pubmed: 28206960
Cochrane Database Syst Rev. 2013 Jun 04;(6):CD001877
pubmed: 23737396
J Clin Oncol. 2015 Jun 20;33(18):2062-71
pubmed: 25964255
BMC Cancer. 2016 Jul 07;16:428
pubmed: 27387327
PLoS One. 2015 Apr 08;10(4):e0122249
pubmed: 25853582
N Engl J Med. 1998 Apr 16;338(16):1089-96
pubmed: 9545356
Clin Transl Oncol. 2018 Apr;20(4):467-475
pubmed: 28808872
N Engl J Med. 2007 Jan 18;356(3):227-36
pubmed: 17229950
J Res Med Sci. 2012 Sep;17(9):850-4
pubmed: 23826012
PLoS One. 2015 May 21;10(5):e0127518
pubmed: 25996938
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Anticancer Res. 2017 Mar;37(3):1501-1505
pubmed: 28314325
Curr Diabetes Rev. 2021 Jan 03;:
pubmed: 33397240
J Clin Med Res. 2017 Mar;9(3):183-187
pubmed: 28179964
Tumour Biol. 2005 Nov-Dec;26(6):281-93
pubmed: 16254457
Med Sci Monit. 2016 Sep 06;22:3154-62
pubmed: 27596019
Growth Factors. 2019 Aug;37(3-4):190-207
pubmed: 31693861
Curr Med Chem. 2014;21(4):501-10
pubmed: 24251561
Carcinogenesis. 2005 May;26(5):900-7
pubmed: 15677629
BMC Cancer. 2018 Mar 27;18(1):328
pubmed: 29580231
Oncotarget. 2017 Oct 10;8(55):94393-94406
pubmed: 29212236
Chin Med J (Engl). 2016 5th Sep;129(17):2026-32
pubmed: 27569226
N Engl J Med. 2016 Oct 13;375(15):1438-1447
pubmed: 27732805
Clin Chem Lab Med. 2013 Jul;51(7):1511-9
pubmed: 23403727
Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3410-5
pubmed: 12624183
Anticancer Res. 2000 Nov-Dec;20(6C):4751-5
pubmed: 11205212